Sun Pharmaceutical Industries Q4 Results

BSE: 524715 | NSE: SUNPHARMA | ISIN: INE044A01036 | Sector: Biotechnology & Drugs

1,191.40 -5.00 (-0.42%)Updated : 28 Nov 2023

Fiscal Period	2023
Period End Date	Mar 23
Revenue	10930.67
Total Revenue	10930.67
Costof Revenue Total	2250.22
Gross Profit	8680.45
Selling/ General/ Admin Expenses Total	2179.55
Depreciation/ Amortization	671.53
Unusual Expense( Income)	171.45
Other Operating Expenses Total	3671.60
Total Operating Expense	8944.35
Operating Income	1986.32
Interest Inc( Exp) Net- Non- Op Total	-1199.10
Other Net	373.28
Net Income Before Taxes	2239.69
Provisionfor Income Taxes	222.91
Net Income After Taxes	2016.78
Minority Interest	1.57
Equity In Affiliates	-338.80
Net Income Before Extra Items	1984.47
Net Income	1984.47
Income Availableto Com Excl Extra Ord	1984.47
Income Availableto Com Incl Extra Ord	1984.47
Diluted Net Income	1984.47
Diluted Weighted Average Shares	238.72
Diluted EPS Excluding Extra Ord Items	8.31
DPS- Common Stock Primary Issue	4.00
Diluted Normalized EPS	8.96